Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Kai, Liu, Bende, Li, Cesheng, Zhang, Huajun, Yu, Ting, Qu, Jieming, Zhou, Min, Chen, Li, Meng, Shengli, Hu, Yong, Peng, Cheng, Yuan, Mingchao, Huang, Jinyan, Wang, Zejun, Yu, Jianhong, Gao, Xiaoxiao, Wang, Dan, Yu, Xiaoqi, Li, Li, Zhang, Jiayou, Wu, Xiao, Li, Bei, Xu, Yanping, Chen, Wei, Peng, Yan, Hu, Yeqin, Lin, Lianzhen, Liu, Xuefei, Huang, Shihe, Zhou, Zhijun, Zhang, Lianghao, Wang, Yue, Zhang, Zhi, Deng, Kun, Xia, Zhiwu, Gong, Qin, Zhang, Wei, Zheng, Xiaobei, Liu, Ying, Yang, Huichuan, Zhou, Dongbo, Yu, Ding, Hou, Jifeng, Shi, Zhengli, Chen, Saijuan, Chen, Zhu, Zhang, Xinxin, Yang, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196837/
https://www.ncbi.nlm.nih.gov/pubmed/32253318
http://dx.doi.org/10.1073/pnas.2004168117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196837/
https://www.ncbi.nlm.nih.gov/pubmed/32253318
http://dx.doi.org/10.1073/pnas.2004168117

Ejemplares similares